Metropolis Healthcare Limited has informed the Exchange about disclosure under Regulation 30 of Listing Regulations

Management Changes View source PDF Explain this filing

METROPOLIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹486.20

prior close

₹484.70

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.2%-0.3% vs market

Healthcare Service Provider peers, median of 22sector+0.1%-0.6% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.6 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.2

15m

-0.4

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.2-0.3+0.1-0.6

Next day

+2.1-0.2+2.3-0.7+2.8

+2.9-0.4+3.4-0.0+3.0

+4.3-0.7+5.1+0.8+3.5

+0.6-2.6+3.2+0.3+0.3

+1.2-3.8+5.0-0.1+1.2

+3.9-2.0+5.9+1.3+2.6

15d

+5.1-6.1+11.2+2.4+2.8

+10.6-3.4+13.9+1.9+8.7

+6.4-2.2+8.6+1.6+4.8

-0.9-3.1+2.2-1.2+0.3

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 22Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Sushil Shah, the founder of Metropolis Healthcare, has stepped down from the honorary position of Chairman Emeritus effective July 18, 2025, citing his age and a desire to enable a smooth transition of responsibilities. He will, however, continue to serve on the Board as a Non-Executive Non-Independent Director, providing guidance on key medical matters. Dr. Shah has been associated with Metropolis for several decades and remains committed to the company's growth. No other board-level changes were announced in this filing.

Likely market impact

This is a soft, pre-planned leadership transition with no disruption to the board — Dr. Shah is not exiting the company, only giving up an honorary title, so shareholders should view this as a neutral to mildly positive move that ensures continuity while bringing in fresh leadership responsibility.